Related Experiment Video
Updated: Jan 30, 2026

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
Published on: June 6, 2025
Stroke Outcomes in the COMPASS Trial
Mukul Sharma1, Robert G Hart1, Stuart J Connolly1
1McMaster University/Population Health Research Institute, Hamilton, Canada (M.S., R.G.H., S.J.C., J.B., O.S., K.K.H.N., L.C., S.Y., J.W.E.).
Insights
The combination of rivaroxaban and aspirin significantly reduced strokes in patients with atherosclerosis compared to aspirin alone. This combination therapy offers a new antithrombotic strategy for stroke prevention.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Neurology
Background:
- The COMPASS trial investigated antithrombotic strategies for patients with stable coronary artery or peripheral artery disease.
- Stroke reduction was a key outcome measure in the trial.
- Previous analyses showed a significant benefit of rivaroxaban plus aspirin over aspirin alone.
Purpose of the Study:
- To present detailed analyses of stroke by type, predictors, and antithrombotic effects in key subgroups from the COMPASS trial.
- To evaluate the efficacy of rivaroxaban plus aspirin versus aspirin alone in preventing different types of strokes.
- To identify independent predictors of stroke in patients with established atherosclerotic disease.
Main Methods:
- A randomized trial involving patients with stable coronary artery or peripheral artery disease.
- Three treatment arms: aspirin 100 mg once daily, rivaroxaban 5 mg twice daily, and rivaroxaban 2.5 mg twice daily plus aspirin.
- Exclusion criteria included need for anticoagulation, recent stroke, lacunar stroke history, or intracerebral hemorrhage.
Main Results:
- The combination of rivaroxaban plus aspirin significantly reduced overall stroke occurrence compared to aspirin alone (HR, 0.58; P<0.0001).
- Ischemic/uncertain strokes were reduced by nearly half with the combination therapy (HR, 0.51; P<0.0001).
- Fatal and disabling strokes were also decreased by the combination (HR, 0.58; P=0.01).
- Prior stroke was the strongest independent predictor of incident stroke (HR, 3.63; P<0.0001).
- The benefit of the combination was consistent across high-stroke-risk subgroups, including those with prior stroke.
Conclusions:
- Low-dose rivaroxaban plus aspirin represents a significant advancement in antithrombotic therapy.
- This combination is an effective option for both primary and secondary stroke prevention in patients with clinical atherosclerosis.
- The findings support the use of rivaroxaban plus aspirin in specific patient populations at high risk for stroke.
Background:
Strokes were significantly reduced by the combination of rivaroxaban plus aspirin in comparison with aspirin in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies). We present detailed analyses of stroke by type, predictors, and antithrombotic effects in key subgroups.
Methods:
Participants had stable coronary artery or peripheral artery disease and were randomly assigned to receive aspirin 100 mg once daily (n=9126), rivaroxaban 5 mg twice daily (n=9117), or rivaroxaban 2.5 mg twice daily plus aspirin (n=9152). Patients who required anticoagulation or had a stroke within 1 month, previous lacunar stroke, or intracerebral hemorrhage were excluded.
Results:
During a mean follow-up of 23 months, fewer patients had strokes in the rivaroxaban plus aspirin group than in the aspirin group (83 [0.9% per year] versus 142 [1.6% per year]; hazard ratio [HR], 0.58; 95% CI, 0.44-0.76; P<0.0001). Ischemic/uncertain strokes were reduced by nearly half (68 [0.7% per year] versus 132 [1.4% per year]; HR, 0.51; 95% CI, 0.38-0.68; P<0.0001) by the combination in comparison with aspirin. No significant difference was noted in the occurrence of stroke in the rivaroxaban alone group in comparison with aspirin: annualized rate of 0.7% (HR, 0.82; 95% CI, 0.65-1.05). The occurrence of fatal and disabling stroke (modified Rankin Scale, 3-6) was decreased by the combination (32 [0.3% per year] versus 55 [0.6% per year]; HR, 0.58; 95% CI, 0.37-0.89; P=0.01). Independent predictors of stroke were prior stroke, hypertension, systolic blood pressure at baseline, age, diabetes mellitus, and Asian ethnicity. Prior stroke was the strongest predictor of incident stroke (HR, 3.63; 95% CI, 2.65-4.97; P<0.0001) and was associated with a 3.4% per year rate of stroke recurrence on aspirin. The effect of the combination in comparison with aspirin was consistent across subgroups with high stroke risk, including those with prior stroke.
Conclusions:
Low-dose rivaroxaban plus aspirin is an important new antithrombotic option for primary and secondary stroke prevention in patients with clinical atherosclerosis.
Clinical Trial Registration:
URL: https://www.clinicaltrials.gov . Unique identifier: NCT01776424.
Related Concept Videos
Compass
Design Example: Marking Boundaries of a Site Using a Compass
Clinical Trials: Overview
Trial and Error and Algorithm
Clinical Trials
There are four phases in a clinical trial. A phase one...
Predicting Reaction Outcomes

